Neurocrine receives breakthrough therapy designation for NBI-98854 in tardive dyskinesia
Neurocrine announced the FDA has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. The designation was granted based on the results of the Phase IIb Kinect studies of NBI-98854 in 220 patients with tardive dyskinesia. October 30, 2014